Serious adverse events · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
RR 0.74 [0.42, 1.3]
Studies not reported
Very low
Serious adverse events
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Serious adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · children with Hirschsprung's disease (HD)
1 finding from 1 review
Serious adverse events · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
1 finding from 1 review
Serious adverse events · adult kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adult patients after liver transplantation.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events · Heterosexual women
It is very uncertain whether the intervention changes serious adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · Heterosexual women
The intervention showed no clear difference in serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · heterosexual women
The intervention showed no clear difference in serious adverse events (low certainty).
1 finding from 1 review
Serious adverse events · people with Duchenne muscular dystrophy and progressive respiratory decline
Idebenone showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adults with P vivax malaria
It is very uncertain whether the intervention changes serious adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with P vivax malaria
It is very uncertain whether the intervention changes serious adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with confirmed clinical and parasitological P vivax malaria
The intervention may leads to higher serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with confirmed clinical and parasitological P vivax malaria
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with confirmed clinical and parasitological P vivax malaria
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with confirmed clinical and parasitological P vivax malaria
1 finding from 1 review
Serious adverse events · advanced hormone‐sensitive prostate cancer
Early showed no clear difference in serious adverse events compared with deferred AST (low certainty).
1 finding from 1 review
Serious adverse events · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people undergoing cystoscopy
It is very uncertain whether antimicrobial changes serious adverse events compared with placebo or no antibiotics (very low certainty).
1 finding from 1 review